AllDocs -> cancers

Adjusted rates 2004 Leukaemia ?91-?95 59 Table 1 General rates, 2004 Incidence: number of new cases 3814 2060 1754 Incidence (crude rate) 8.0 9.4 6.9 Incidence (age-standardised, world standard) 6.2 7.9 5.0 Incidence (age-standardised, Ukrainian standard) 7.8 10.5 6.1 Change of incidence rate 2004 in comparison with 2003 (age-standardized rates, Ukrainian standard, %) 1.30 0.09 3.55 Mortality: number of new cases 2526 1427 1099 Mortality (crude rate) 5.3 6.5 4.3 Mortality (age-standardised, world standard) 3.8 5.2 2.8 Mortality (age-standardised, Ukrainian standard) 5.1 7.4 3.8 Lived less than 1 year since the diagnosis in 2004, % 40.7 40.4 41.0 From among the newly diagnosed – diagnosed ...

Do electric and magnetic fields cause childhood leukaemia ? A review of the scientific evidence Prepared for CHILDREN with LEUKAEMIA by Dr Adrienne Morgan and Katie Martin BSc Registered Charity No. 298405. Inaugurated in 1988 by Diana, Princess of Wales in memory of Jean and Paul O’Gorman CHILDREN with LEUKAEMIA Fighting Britain’s biggest child killer disease Magnetic fields document 24/5/06 3:59 pm Page 1 Page 2 2 Contents Contents page Executive summary 4 1 Introduction 5 1.1 Electric and Magnetic fields 5 1.1.1 Magnetic fields 6 1.1.2 Electric fields 6 1.2 Childhood leukaemia 6 1.2.1 Types of childhood leukaemia 6 1.2.2 The genetic basis of leukaemia 7 1.2.3 Incidence ...

Institute of Child Health & Great Ormond Street Hospital Molecular Basis of Childhood Leukaemia Thursday 23 – Friday 24 March 2006 Provisional Programme Thursday 23 rd March 2006 09.45 Introduction Hugh Brady, Institute of Child Health The MLL Gene and Leukaemia 10.00 MLL fusion genes: what do they tell us about acute leukaemia ? Eric So, Institute of Cancer Research, London 10.40.1 MLL fusions in leukaemia : different proteins, one function? Robert Slany, University of Erlangen 11.20 T E A / C O F F E E 11.50 Pathological mechanisms in t(4;11) leukaemia : new insights and perspectives Rolf Marschalek, University of Frankfurt 12.30 MLL - Leukaemia and Epigenetices Jay Hess, University of Michigam 13.10.1 L U N C H Page 2 Acute ...

Discovery and molecular targeting of Discovery and molecular targeting of oncogenes involved in myeloid oncogenes involved in myeloid leukaemia leukaemia 1. Retroviral expression cloning to identify novel oncogenes 2. The Myb oncoprotein as a potential target Page 2 Myeloid Leukaemias Myeloid Leukaemias Acute Myeloid Leukaemia • Accumulation of immature granulocyte and macrophage progenitors in bone marrow and peripheral blood • Heterogeneous (several subtypes) • Cure rate 20-45% with conventional chemotherapy - complications/toxicity • No targeted therapy in regular use – cf. Glivec for CML Page 3 Myeloid Leukaemias Myeloid Leukaemias continued continued ...

MEMBER of International Federation of Biomedical Laboratory Science, IFBLS Non-Governmental Organization in Official Relationship with the World Health Organization, W.H.O. The Role of Molecular Diagnostics in New Leukaemia and Carcinoma Treatments Targeting Tyrosine Kinases will be delivered by Lap Ping CHUNG BSc (Liv), DPhil (Oxon) Scientific Officer Department of Pathology Queen Mary Hospital The University of Hong Kong on Thursday, 27 th October 2005 at 7:00 P.M. in Lecture Hall Federation of Medical Societies of Hong Kong 4th Floor, Duke of Windsor Social Service Building 15 Hennessy Road, Wanchai, Hong Kong HKIMLS CPD Accreditation: 1 point MLT Board CPD: 1 Point Programme/Activity Code: 07050111 ALL INTERESTED ARE WELCOME

Prof. Martin F. Fey Institute of Medical Oncology University and Inselspital Bern Switzerland Leukaemia Leukaemia & & Lymphoma Lymphoma Page 2 Browse through recent progress in • Hodgkin‘s disease • Molecular biology of – B-cell NHL – AML • Myeloma Page 3 Hodgkin‘s disease Page 4 Hodgkin‘s disease • MOPP ABVD • High-dose chemotherapy in refractory / relapsed HD ? How to improve ABVD ? A ssess B EACOPP from V olker D iehl Page 5 German Hodgkin Study Group Standard COPP/ABVD Standard COPP/ABVD BEACOPP BEACOPP BEACOPP ...

121 Leukaemia 18 18.1. INTRODUCTION AND SUMMARY Table 18.1. Summary of incidence and mortality statistics: leukaemia INCIDENT CASES DEATHS males females both sexes males females both sexes All cancers (ICD-O 2 C42.1, M-9800 to M-9941 and ICD-10 C91 to C95) 1997 cases 195 144 339 124 90 214 % of all cancers 1.8% 1.3% 1.6% 3.1% 2.5% 2.8% Incidence and mortality rates (per 100,000 persons per year) crude rate 10.8 7.8 9.3 6.9 4.9 5.9 World age-standardised rate 8.9 6.2 5.4 3.2 European age-standardised rate 12.0 7.5 7.8 4.3 cumulative risk (0-74) 0.8% 0.5% 0.5% 0.3% mortality/incidence ratio 0.636 0.625 0.631 Time trends (all cancers) 1994 cases ...

leukaemia 1581 Chronic myeloid leukaemia Chronic myeloid leukaemia THE STORY OF CHRONIC MYELOID LEUKAEMIA ‘It is moreover, the same conclusion which Bennett came to in the much-discussed matter of priority between us when he observed a case of indubitable leukaemia , some months before I saw my first case'. With these words, spoken at a lecture in Berlin in 1858, Robert Virchow generously acknowledged that John Hughes Bennett's description of chronic myeloid leukaemia in Edinburgh in 1845 preceded his by a short period and called a truce to the unseemly controversy which had marred its discovery.’ Rudolf Virchow (1821-1902) Chronic myeloid leukaemia The patient , a 49yr old teacher, saw her family physician because of fatigue for about six months. ...

95 RECENT ADVANCES IN THE THERAPY OF ACUTE LEUKAEMIA * HAU C. KWAAN, M.D., F.R.C.P. (EDIN.), F.A.C.P. From the Department of Medicine, Northwestern University Medical School, and the Haematology Section, Veterans Administration Research Hospital, Chicago, Illinois, U.S.A. In recent years, significant advances have been made in the understanding of malignant diseases; leading to significant improvements in the survival rate. Among the various neoplastic conditions the improvements in the morbidity and mortality figures in acute leukaemia show perhaps the best results. While the diagnosis of acute leukaemia carried with it grave prognostic implications as recently as ten years ago, it is possible today to speak of a "cure” with chemo- therapy. I would like to discuss the following key factors that are contributing ...

LEUKAEMIA TARGET 44643 ABPI Target Leukaemia 13/5/04 8:46 Page 1 Page 2 The Association of the British Pharmaceutical Industry 12 Whitehall London SW1A 2DY Telephone: 020 7930 3477 Fax: 020 7747 1411 E-mail: abpi@abpi.org.uk Website: www.abpi.org.uk Researched and written by Dr Mike Hall Target Series Editor: Bill Kirkness Acknowledgements The ABPI wishes to thank member companies for the help given in the preparation of this booklet. We are also indebted to Leukaemia Care for their helpful advice and comments on the draft text. In particular, we are grateful to Dr Charles Stiller of the Childhood Cancer Research Group, University of Oxford, for the graphs showing survival in childhood leukaemia , and to the UK Child Cancer Study Group for the figure of overall survival in children. Thanks ...

Our achievements in blood cell cancer research Over the past 25 years or so, The Institute and the Royal Marsden have achieved a notable track record in haemato-oncology research. Under Professor Ray Powles, the previous Head of the Leukaemia and Myeloma Units, the first European bone marrow transplant programme was established in the 1970s. Following his appointment in 1988 as Chair of the Academic Department of Haematology and Cytogenetics, Professor Daniel Catovsky established our campus as a leading centre for laboratory research on and treatment of chronic lymphocytic leukaemia . Since arriving in the Chester Beatty Laboratories some 20 years ago, my own team in the Leukaemia Research Fund Centre has focused on the cell and molecular biology of childhood leukaemia . In the past year we have witnessed the culmination of our efforts over a long period ...

Hodgkin’s lymphoma & other lymphomas myeloma • myelodysplasia • aplastic anaemia the myeloproliferative disorders • the leukaemias Revised Sep 2003 Page 2 Acknowledgements The Leukaemia Research Fund gratefully acknowledges the help and advice of many clinicians who have generously given their time to aid in preparation of our patient information publications. A list can be found at www.lrf.org.uk/advisors/ Published by Leukaemia Research Fund , April 2001 43 Great Ormond Street London WC1N 3JJ Tel: 020 7405 0101 Email: info@lrf.org.uk Fax: 020 7242 1488 Web: www.lrf.org.uk Registered Charity 216032 Revised and Reprinted September 2003 © All rights reserved. No part of this publication may be reproduced or transmitted without permission in writing from Leukaemia Research Fund. Series Author: Ken ...

abc H o d g k i n ’s disease & other lymphomas myeloma • myelodysplasia • aplastic anaemia the myeloproliferative disorders • the leukaemias Page 2 Acknowledgements Leukaemia Research Fund gratefully acknowledges the help and advice of Professor A. V. Hoffbrand in reviewing this series of publications and the assistance of Professor A. Burnett, Professor D. Catovsky, Professor J. Chessells, Professor J. Goldman, Dr A. Haynes, Professor G. Morg a n , Dr S. O’Brien, and Professor J. Sweetenham in the preparation of specific titles. Published by Leukaemia Research Fund , April 2001 43 Great Ormond Street L o n d o n WC1N 3JJ Tel: 020 7405 0101 Email: info@lrf.org . u k Fax: 020 7242 1488 Web: www. l r f . o rg . u k Registered Charity 216032 © All rights reserved. No part of this publication may be reproduced or transmitted ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int EMEA 2006 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 9 June 2006 Doc.Ref.: EMEA/COMP/137639/2006draft COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF nilotinib for the treatment of chronic myeloid leukaemia On 22 May 2006, orphan designation (EU/3/06/375) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for nilotinib for the treatment of chronic myeloid leukaemia . What is chronic myeloid leukaemia ? Chronic myeloid leukemia ...

leukaemia 1185 ( To be on headed paper) Medical Research Council Acute Lymphoblastic Leukaemia Trial XII Version3.0 May 2005 Patient information sheet You are being invited to take part in a research study. Before you decide it is important for you to understand why the research is being done and what it will involve. Please take time to read the following information carefully and discuss it with others if you wish. Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish to take part. Thank you for reading this. What is the purpose of the study? The purpose of this study is to find out more about how best to treat patients with Acute Lymphoblastic Leukaemia (ALL). The more people who take part in these studies, the better the information that we are able to obtain and the ...

leukaemia 1185 (To be on headed paper) Medical Research Council Acute Lymphoblastic Leukaemia Trial XII Version 4.0 May 2005 Parent / Guardian Information Sheet Your child is being invited to take part in a research study. Before you and your child decide it is important for you both to understand why the research is being done and what it will involve. Please take time to read the following information carefully and discuss it with others if you wish. Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish your child to take part. Thank you for reading this. What is the purpose of the study? The purpose of this study is to find out more about how best to treat patients with Acute Lymphoblastic Leukaemia (ALL). The more people who take part in these studies, the better the information ...

The Leukaemia Foundation • The Leukaemia Foundation is the only national not-for-profit organisation dedicated to the care and cure of patients and families living with leukaemias, lymphomas, myeloma and related blood disorders. How these diseases change lives • Approximately 7,300 people are diagnosed with leukaemias, lymphomas and myeloma each year; the equivalent of 20 people per day. Of these, approximately 53% are diagnosed with lymphomas, 33% with leukaemias and another 14% with myeloma. • The diseases often develop with little warning, requiring immediate and intensive treatment. In acute cases, families often need to uproot their lives and relocate virtually overnight. In reality it means leaving work, school, family commitments and friends while dealing with the emotional turmoil of diagnosis and immediate treatment. • They can develop in anyone, of any age, at any time. ...

Leukaemia Foundation CommunityFundraisingGuidelines These guidelineshave been developed to assist groupsand individualswho are developing fundraisingactivitiesto benefit the Leukaemia Foundation. Theyare an essentialpart ofyourplanningand you must ensure you willbe able to comply withthese guidelinesBEFOREundertakingyourfundraisingactivity. These guidelinesare designed to protect the public,the ActivityOrganiserand the Leukaemia Foundation from unnecessaryrisk.Ifyou have anyquestions,please contact the Fundraising Coordinatorin yourLeukaemia Foundation state office. Thank you forofferingto support the Leukaemia Foundation 1. These guidelines provide the basisforafundraisingactivitytobe organisedbythe Activity Organiseron behalfofthe LeukaemiaFoundation.Ifaccepted,bysigningandreturningthe CommunityFundraisingProposalandAgreement,these FundraisingGuidelines willform the terms andconditions ofthe fund...

Leukaemias FactSheet • Leukaemia candevelopinanyone, ofanyage, atanytime. • Approximately2,370Australians arediagnosedwithleukaemias everyyear; theequivalentof6peopleeveryday. • Approximately1,363Australians willdieofleukaemias everyyear;the equivalentofalmost4peopleeveryday. • Leukaemias arethemostcommonform ofchildhoodcanceryetmorethan 90% ofAustralians diagnosedwithleukaemia areadults. • Whencomparedwithothercancers, leukaemia affects a largerproportionof childrenthanolderagegroups. • Leukaemias oftendevelopwithlittlewarning, requiringimmediateand intensivetreatment.Patients withacuteleukaemia typicallybegintreatment within24hours ofdiagnosis. • Factors thatmayaffectleukaemia‘sdevelopmentarenotclearbutmay includea person‘sgenetichistory, exposuretointenseradiationandcertain chemicalsandviruses liketheHumanT-CellLeukaemia virus. Whatareleukaemias? ...

Oct 05 This information booklet is produced by the Leukaemia Foundation and is one in a series on blood cancers and related disorders. Some booklets are also available in other languages. Copies of this booklet and the other booklets can be obtained from the Leukaemia Foundation in your state by contacting us on Freecall: 1800 620 420 Email: info@ leukaemia .com Website: www. leukaemia .com The Leukaemia Foundation is a non-profit organisation that depends on donations and support from the community. Please support our work by calling 1800 620 420 or by mailing your donation to: The Leukaemia Foundation GPO Box 9954 in your capital city Understanding Acute Myeloid Leukaemia (AML) A guide for patients, carers and families Page 2 Oct 05 This information booklet is produced by the Leukaemia ...

March 2005 CHRONIC MYELOGENOUS LEUKAEMIA CHRONIC MYELOGENOUS LEUKAEMIA 1 1 st st ALLOGENEIC TRANSPLANT (HLA ALLOGENEIC TRANSPLANT (HLA - - Identical sibling or unrelated donor) Identical sibling or unrelated donor) RELAPSE INCIDENCE ACCORDING TO THE PERIOD OF TRANSPLANT RELAPSE INCIDENCE ACCORDING TO THE PERIOD OF TRANSPLANT Relapse Incidence Years from transplant Years from transplant 14 14 12 12 10 10 8 8 6 6 4 4 2 2 0 0 .0 .0 .2 .2 .4 .4 .6 .6 .8 .8 1.0 1.0 Period of Period of No. No. No. No. Transplant Total Relapse HR (95%CI) Transplant Total Relapse HR (95%CI) 1992 1992 - - 96 96 3709 ...

8. Hehlmann R, et al. Randomized comparision of Inter- feron-Alpha with Busulfan and Hydroxyurea in chronic myelogenous leukemia (CML). Blood 1994; 84: 382a 9. Fujita T, Kimura Y, Miyamoto M, et al. Induction of endogenous IFN-a and IFN-ß genes by a regulatory trans- cription factor, IRF-1. Nature 1989; 337: 270-272. 10. Fujita T, Reis LF, Watanabe N, et al. Induction of the transcription factor IRF-1 and interferon mRNAs by cyto- kines and activators of second-messenger pathways. Proc Natl Acad Sci USA 1989; 86: 729-739. 11. Carella AM, Podesta M, Frassoni F, et al. Collection of "normal" blood repopulating cells during early hema- topoietic recovery after intensive conventional chemo- therapy in chronic myelogenous leukemia. Bone Marrow Transplantation 1993; 12: 267-271. 12. McGlave PB, De Fabritis P, Deisseroth A, et al. Auto- logous transplants for chronic myelogenous leukaemia : results ...

2 CHRONIC MYELOID LEUKAEMIA 1.0 stick PATIENT label here 2.0 Referral Details 2.1 2.2 G.P. specify_ 2.3 2.4 Clinical Presentation (specify) __ 2.4.1 2.5 Provisional diagnosis : _ 2.6 Yes No specify _ 2.7 Previous: Radiotherapy other specify 2.8 Strong family history of any malignant disease Yes No UNK If YES 2 or more 1st degree relatives: 2.9 Previous solid organ transplant Yes No Generic Data Items HAEMATOLOGY Minimum Cancer Data Set :- Chemotherapy Date of receipt of referral __ Referred to Source of referral Cons.to Cons. Self Referral Other inc Private DATE OF 1st APPOINTMENT Previous or concurrent malignant disease: Diagnosis & Treatment initiated elsewhere no need to complete. signature ...

HK J Paediatr (new series) 2006; 11 :69-72 Cerebral Infarction in Childhood Acute Lymphoblastic Leukaemia Treated with Low Dose E. coli Asparaginase LM P ESQUERA -L EPATAN , GCF C HAN , C L AM , MHK H O , TL L EE , AKS C HIANG , SY H A , YL L AU Section of Pediatric Hematology and Oncology, Santo Tomas University Hospital, Manila, Philippines LM P ESQUERA -L EPATAN MD Department of Paediatrics & Adolescent Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, China GCF C HAN MD, FHKAM(Paed), FRCPCH(UK) MHK H O ...